Pharmazone Lab Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-07-2024
- Paid Up Capital ₹ 0.50 M
as on 30-07-2024
- Company Age 10 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 52.36%
(FY 2023)
- Profit 902.66%
(FY 2023)
- Ebitda 706.21%
(FY 2023)
- Net Worth 23.47%
(FY 2023)
- Total Assets -1.67%
(FY 2023)
About Pharmazone Lab
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Prabhash Pani, Rajanikanta Samantray, and Mohammed Kasim serve as directors at the Company.
- CIN/LLPIN
U24232OR2014PLC018423
- Company No.
018423
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
13 Nov 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Bhubaneswar, Orissa, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Pharmazone Lab Limited offer?
Pharmazone Lab Limited offers a wide range of products and services, including Eye Care Medicines, Eye Drops, Carboxymethylcellulose Sodium Eye Drops, Antiemetic Drugs, Domperidone Tablet, Antacid Drugs, Rabeprazole Tablets.
Who are the key members and board of directors at Pharmazone Lab?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhash Pani  | Director | 13-Nov-2014 | Current |
| Rajanikanta Samantray | Director | 13-Nov-2014 | Current |
| Mohammed Kasim | Director | 04-Apr-2019 | Current |
Financial Performance of Pharmazone Lab.
Pharmazone Lab Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 52.36% increase. The company also saw a substantial improvement in profitability, with a 902.66% increase in profit. The company's net worth Soared by an impressive increase of 23.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Pharmazone Lab?
In 2023, Pharmazone Lab had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kar Medical Private LimitedActive 17 years 3 monthsPrabhash Pani and Rajanikanta Samantray are mutual person
- Pro Force Security Services Private LimitedActive 14 years 3 months
Prabhash Pani is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Pharmazone Lab?
Pharmazone Lab has a workforce of 13 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Pharmazone Lab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Pharmazone Lab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
